Tim Joslin

BSc(Hons), ARCS
Head of Portfolio Management and Commercial Strategy

Tim is Portfolio Management and Commercial Strategy & Head of Internal Medicine and Respiratory at tranScrip. He has over 40 years’ experience in the pharmaceutical industry across various functions and increasing levels of seniority in UK, Europe and US. 

Throughout his career Tim has held a number of senior positions in big pharma companies at a national, regional and global level as well as providing independent business consulting services. During this time, he led multifunctional teams conducting commercial assessments, development and launch of many anti-infective, (including antibiotics and antifungals), respiratory & allergy and novel cardiovascular agents. 

Tim has experience of the entire product life cycle for large and orphan indications – from development of target product profiles with research teams, through scientific, clinical and commercial evaluations of assets prior to phase transitions, pre/peri and post-launch activities at a National and Global level and post patent planning and execution to maximise profitability while maintaining sales volumes. 

This significant experience is brought to bear for tranScrip’s client projects focused primarily on the US and European markets. Within tranScrip Tim heads the Internal Medicine and Respiratory franchise and leads multifunctional project teams to answer client’s key scientific, clinical and regulatory questions (including Scientific Advice meetings with FDA, EMA and National Agencies) about developmental and marketed products in this broad therapeutic category and also for projects across a wide variety of other therapeutic areas.

Using his specific expertise from big pharma/consulting, Tim has led many commercial assessments of products and/or companies across a wide spectrum of therapeutic areas. These projects have included analysis of the science, clinical development potential, commercial differentiation and pricing and reimbursement which have been used as a firm basis for construction of patient based peak sales forecasts to guide clients as to the potential of assets within the lead indication and alternative opportunities.

Before joining tranScrip, he spent 25 years in big pharma companies, the last 12 years at RPR/Aventis/sanofi-aventis in UK, France and the USA. Where he worked variously as the Global Director of Anti-infectives, Global Director New Products (anti-infective and Cardiovascular), Head of Anti-infectives Europe. He then spent 6 years at Defined Health as the Managing Director Europe, responsible for commercial assessment of assets in the anti-infective, respiratory, CNS and orphan fields, working in both in Europe and the USA.  Tim graduated from Imperial college of Science and Technology with a focus on Zoology and Parasitology.